Switching From or To Flibanserin (Addyi): Protocols, Timelines, and What to Expect

How Flibanserin Works: Mechanism That Shapes Switching Decisions

Flibanserin acts on three neurotransmitter systems simultaneously, which is why switching to or from it demands more caution than switching between two drugs that share a single target. It is a full agonist at the serotonin 5-HT1A receptor, an antagonist at the 5-HT2A receptor, and a weak antagonist at dopamine D4 receptors [1]. The net effect is a transient increase in dopamine and norepinephrine in the prefrontal cortex, paired with a reduction in serotonin release [2].

Why the Mechanism Matters for Switching

This mixed serotonergic profile creates two practical concerns when transitioning medications. First, overlapping serotonin activity with another serotonergic drug (SSRIs, SNRIs, trazodone, tramadol) raises the theoretical risk of serotonin syndrome. Second, the dopamine and norepinephrine effects can interact with stimulants, bupropion, or MAO inhibitors in ways that standard SSRI-to-SSRI switching protocols do not address.

Onset and Offset Kinetics

Flibanserin reaches steady-state plasma concentrations after approximately 3 days of nightly dosing [1]. Its elimination half-life is roughly 11 hours in most women, though CYP3A4 poor metabolizers or patients taking moderate CYP3A4 inhibitors may experience delayed clearance up to 26 hours [3]. Five half-lives, the standard pharmacokinetic benchmark for near-complete elimination, translates to approximately 55 hours (about 2.3 days) for typical metabolizers.

When to Consider Switching Away From Flibanserin

The FDA label recommends discontinuing flibanserin if no improvement occurs after 8 weeks of nightly use [1]. In the BEGONIA trial (N=1,087), the drug separated from placebo on the desire domain of the Female Sexual Function Index by week 4, with full effect emerging by week 8 [4]. Stopping before that window risks abandoning a medication that simply has not reached efficacy.

Inadequate Response

An inadequate response means fewer than two additional satisfying sexual events per month above baseline after a full 8-week course. BEGONIA reported a mean increase of 0.8 satisfying events per month over placebo, with roughly 46% of patients meeting a clinically meaningful threshold versus 34% on placebo [4]. If a patient falls outside that responder group after 8 weeks, switching becomes reasonable.

Intolerable Side Effects

The most common reasons patients discontinue flibanserin are somnolence (reported in 11.4% vs. 3.1% placebo), dizziness (11.4% vs. 2.2%), and nausea (10.4% vs. 3.9%) [1]. These effects often diminish after the first 2 weeks but can persist. If bedtime dosing adjustments and dose timing optimization fail to control symptoms, switching is appropriate.

Alcohol-Related Lifestyle Conflict

Flibanserin carries a boxed warning against any alcohol use due to the risk of severe hypotension and syncope [1]. The original REMS program (discontinued June 2019 after an FDA review) required prescriber certification around this interaction [5]. For patients who find total alcohol abstinence unsustainable, bremelanotide offers an alternative without this restriction.

Switching From Flibanserin to Bremelanotide (Vyleesi)

Bremelanotide is the only other FDA-approved drug for premenopausal HSDD, making it the most common switch target. It works through an entirely different pathway: melanocortin-4 receptor agonism [6]. Because there is no serotonergic overlap, the pharmacologic risk of the transition is low.

Recommended Washout Protocol

No randomized trial has studied a direct flibanserin-to-bremelanotide switch. Based on flibanserin's 11-hour half-life, a minimum 2-day washout (approximately 5 half-lives) ensures plasma concentrations fall below clinically active levels [1]. Conservative clinicians extend this to 3 days for CYP3A4 poor metabolizers or patients taking fluconazole, erythromycin, or other moderate CYP3A4 inhibitors.

Bremelanotide Initiation After Washout

Bremelanotide is dosed as needed (1.75 mg subcutaneous injection, at least 45 minutes before anticipated sexual activity), with a maximum of one dose per 24 hours and no more than 8 doses per month [6]. Because it is PRN rather than daily, patients can begin their first dose on the day after washout completion. No titration is required.

Monitoring the Transition

Blood pressure should be checked before the first bremelanotide dose. The RECONNECT trials (N=1,247) showed a transient mean increase of 2.5 mmHg systolic and 1.4 mmHg diastolic, peaking 2 to 3 hours after injection and resolving within 12 hours [7]. Patients with uncontrolled hypertension (systolic ≥160 or diastolic ≥100) or known cardiovascular disease should not receive bremelanotide [6].

Switching From Bremelanotide to Flibanserin

The reverse switch, from bremelanotide to flibanserin, is pharmacokinetically simpler. Bremelanotide has a half-life of 2.7 hours and is used on demand, so no formal washout is needed if the last bremelanotide dose was taken more than 12 hours prior [6].

Starting Flibanserin After Bremelanotide

Flibanserin is initiated at 100 mg nightly at bedtime. Patients should be counseled that efficacy assessment requires a minimum 8-week commitment to nightly dosing and that the alcohol contraindication begins immediately on the first dose [1]. The "Prescribing Information for Addyi" recommends taking flibanserin at bedtime to minimize the risk of hypotension, somnolence, and accidental injury from CNS depression.

Setting Expectations

Because flibanserin's benefit accumulates over weeks while bremelanotide's effect is immediate (within 45 to 60 minutes of injection), patients switching from bremelanotide should expect a gap period where neither drug is providing full therapeutic effect. Framing this transition realistically reduces premature discontinuation.

Switching Between Flibanserin and Off-Label HSDD Treatments

Several drugs are used off-label for HSDD despite lacking FDA approval for this indication. Switching between flibanserin and these agents requires attention to overlapping mechanisms.

Bupropion

Bupropion (a norepinephrine-dopamine reuptake inhibitor) is the most commonly prescribed off-label option for low desire. A 2008 trial by Safarinejad (N=218) found bupropion 150 mg twice daily improved desire scores in SSRI-treated women with sexual dysfunction [8]. Because both bupropion and flibanserin increase prefrontal dopamine tone, their effects may compound. No washout is strictly required when switching from flibanserin to bupropion, but starting bupropion the day after flibanserin's last dose, rather than overlapping, is preferred to avoid excessive dopaminergic stimulation (insomnia, agitation).

Testosterone (Off-Label)

The International Society for the Study of Women's Sexual Health (ISSWSH) 2022 process of care recommends off-label transdermal testosterone (300 mcg/day) for postmenopausal HSDD when approved therapies fail [9]. Testosterone has no serotonergic activity, so no washout from flibanserin is needed. The two drugs can theoretically be co-administered, though no combination trial data exist.

SSRIs and SNRIs

This scenario most commonly arises when a patient on an SSRI/SNRI for depression develops HSDD as a medication side effect and is prescribed flibanserin. The FDA label explicitly warns against concurrent use with any serotonergic drug due to serotonin syndrome risk [1]. Switching from an SSRI to flibanserin requires completing the SSRI's recommended taper and washout first. For fluoxetine, with its 4-to-6-day active metabolite half-life, this means a 5-week washout. For shorter-acting SSRIs (sertraline, escitalopram), 2 weeks is standard practice per APA guidelines [10].

Factors That Influence Switching Success

CYP3A4 Interactions

Flibanserin is primarily metabolized by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) are contraindicated because they increase flibanserin AUC by approximately 4.5-fold [1]. Moderate inhibitors (fluconazole, erythromycin, diltiazem, grapefruit juice in large quantities) increase AUC roughly 2-fold. When switching from flibanserin to any drug, residual CYP3A4 inhibition can prolong flibanserin's clearance. Document the patient's full medication and supplement list before switching.

Hepatic Impairment

Patients with hepatic impairment are contraindicated from flibanserin use entirely [1]. Flibanserin exposure increases 4.5-fold in Child-Pugh B cirrhosis. If a patient developed hepatic impairment while on flibanserin, discontinuation followed by a 3-to-5-day extended washout (rather than 2 days) is warranted before initiating an alternative. Bremelanotide does not carry a hepatic impairment contraindication, making it the safer option in this population [6].

Psychiatric Comorbidities

Depression, anxiety, and relationship distress frequently co-occur with HSDD. The BEGONIA and DAISY trials both excluded women taking antidepressants, limiting evidence on flibanserin's safety in this population [4]. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction recommends addressing psychiatric comorbidities before attributing low desire solely to HSDD and prescribing pharmacotherapy [11].

Step-by-Step Switching Checklist

This protocol applies to the most common switch: flibanserin to bremelanotide. Adjust for the scenarios outlined above.

1. Confirm the patient has completed at least 8 weeks of nightly flibanserin dosing
2. Document the reason for switching (inadequate response, side effects, alcohol contraindication)
3. Stop flibanserin. Last dose should be taken at bedtime as usual
4. Observe a minimum 2-day washout (extend to 3 to 5 days if CYP3A4 inhibitors are present or hepatic function is impaired)
5. Maintain the alcohol restriction through the washout period until flibanserin is fully eliminated
6. Check blood pressure before the first bremelanotide dose
7. Administer bremelanotide 1.75 mg subcutaneously at least 45 minutes before anticipated activity
8. Schedule follow-up at 4 weeks to assess response, nausea (reported in 40% of RECONNECT participants), and injection-site reactions [7]

What the Evidence Does Not Cover

No head-to-head trial has compared flibanserin directly with bremelanotide. The closest indirect comparison comes from a 2020 network meta-analysis by Jaspers et al., which estimated that both drugs produce small but statistically significant improvements in desire, with overlapping confidence intervals [12]. Without direct comparison data, treatment selection relies on patient preference (daily pill vs. PRN injection), side-effect profile, alcohol use, and insurance formulary placement.

No switching protocol has been validated in a prospective study. The recommendations in this article are derived from pharmacokinetic parameters, FDA labeling, and expert clinical consensus. Clinicians should exercise judgment and monitor patients closely during any transition.

Patients prescribed flibanserin who are also taking CYP2C19 poor-metabolizer substrates should have their genotype documented before switching, as flibanserin weakly inhibits CYP2C19 at therapeutic concentrations [1].